Blepharitis induced by epidermal growth factor receptor-targeting therapy.
Ulusakarya
Ayhan
A
Department of Hematology/Oncology, Paul Brousse Hospital, Villejuif, France. ayhan.ulusakarya@pbr.ap-hop-paris.fr
Gumus
Yusuf
Y
Delmas-Marsalet
Béatrice
B
Machover
David
D
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001762:Blepharitis / Q000139:chemically induced*; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D000068818:Cetuximab